Alexion Pharmaceuticals (NASDAQ:ALXN) says Japan’s Ministry of Health, Labour and Welfare has approved the extension of the current marketing authorization of Soliris (eculizumab) for the prevention of relapse in patients with NMOSD, autoimmune disorder that causes inflammation in the optic nerve and spinal cord.
The company says Soliris is the only approved medication in Japan for NMOSD.
The approval of Soliris was based on comprehensive results from the Phase 3 randomized, double-blind placebo controlled Prevent trial and a long-term extension study which is still underway.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.